{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:54:52Z","timestamp":1787165692621,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Arrhythmia is a type of cardiovascular disorder that can be fatal. Several methods for treating cardiac arrhythmia have been developed, the most significant of which are implantable cardiac defibrillator (ICD) placement and pharmaceutical therapy. The present study aimed to analyze the cost-effectiveness of an ICD strategy compared to the pharmaceutical therapy in patients with arrhythmia in Iran.This is an economic evaluation study that was carried out using the Markov model for lifetime time horizon. The study population includes all patients with cardiac arrhythmia hospitalized in Shafa hospital in Kerman, eastern-south of Iran, between 2017 and 2019. The study sample includes 101 patients who were treated using the ICD method and 101 randomly selected patients who were received pharmaceutical treatment. This study is conducted from the perspective of the health system, and only direct costs (medical and non-medical) are derived. The study\u2019s outcome was defined as the quality-adjusted life-year (QALY). The data was analyzed using TreeAge software version 2020, and the incremental cost-effectiveness ratio (ICER) was compared to a willingness-to-pay (WTP) threshold of three times GDP per capita in 2021 ($13,002). Deterministic and probabilistic sensitivity analyses were performed to examine the effect of uncertain model parameters on cost effectiveness anlysis. The results revealed that the lifetime costs of ICD and pharmaceutical therapy strategies in treating cardiac arrhythmia were $41,135 and $8,592, respectively, with outcomes equal to 12.63 and 11.29 QALYs. The ICER of the ICD strategy compared to the pharmaceutical therapy was $24,286 per QALY, and it was not cost-effective. The probabilistic sensitivity analysis demonstrated that at a WTP of three times the GDP per capita, the ICD approach had a 40% cost-effectiveness probability. According to the findings of this study, the ICD strategy, when compared to pharmaceutical therapy, is not cost-effective for the treatment of patients with cardiac arrhythmia in Iran. Resource allocation and cost-cutting measures must be implemented as needed.<\/jats:p>","DOI":"10.1186\/s12962-025-00661-5","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T09:56:42Z","timestamp":1760522202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness analysis of an implantable cardiac defibrillator compared with pharmaceutical therapy in patients hospitalized with arrhythmia in Iran"],"prefix":"10.1186","volume":"23","author":[{"given":"Tayyebeh","family":"Nowruzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Goudarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Aliramezany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza Harandi","family":"Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholamreza","family":"Bazmandegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Najafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"10","key":"661_CR1","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1111\/j.1365-3156.2008.02116.x","volume":"13","author":"JJ Miranda","year":"2008","unstructured":"Miranda JJ, Kinra S, Casas JP, Davey Smith G, Ebrahim S. Non-communicable diseases in low- and middle-income countries: context, determinants and health policy. Trop Med Int Health. 2008;13(10):1225\u201334.","journal-title":"Trop Med Int Health"},{"key":"661_CR2","unstructured":"World health organization. Noncommunicable diseases. 2020 [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/noncommunicable-diseases]"},{"key":"661_CR3","unstructured":"Thedacare. Types of heart & vascular diseases. 2020 [Available from: https:\/\/www.thedacare.org\/Health-Library-and-Conditions\/cardiovascular\/common-conditions-and-risks\/Types-of-Heart-and-Vascular-Diseases.aspx]"},{"issue":"2","key":"661_CR4","first-page":"14","volume":"2","author":"S Shahsavari","year":"2013","unstructured":"Shahsavari S, Nazari F, Karimyar Jahromi M, Sadeghi M. Epidemiologic study of hospitalized cardiovascular patients in Jahrom hospitals in 2012\u20132013. Iran J Cardiovasc Nurs. 2013;2(2):14\u201321. [In Persian].","journal-title":"Iran J Cardiovasc Nurs"},{"issue":"4","key":"661_CR5","first-page":"204","volume":"22","author":"N Sarrafzadegan","year":"2019","unstructured":"Sarrafzadegan N, Mohammmadifard N. Cardiovascular disease in Iran in the last 40 years: Prevalence, Mortality, Morbidity, challenges and strategies for cardiovascular prevention. Arch Iran Med. 2019;22(4):204\u201310.","journal-title":"Arch Iran Med"},{"issue":"2","key":"661_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.15420\/aer.2018:15:2","volume":"7","author":"NT Srinivasan","year":"2018","unstructured":"Srinivasan NT, Schilling RJ. Sudden cardiac death and arrhythmias. Arrhythm Electrophysiol Rev. 2018;7(2):111\u20137.","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"661_CR7","unstructured":"Heart Rhythmalliance. Types of arrhythmia. 2020 [Available from: https:\/\/www.heartrhythmalliance.org\/aa\/uk\/types-of-arrhythmia]"},{"key":"661_CR8","unstructured":"Rang HP, Dale MM, Lamb P, Ritter JM, Moore P. Pharmacology: Churchill Livingstone. 2003."},{"issue":"6","key":"661_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2165\/00002018-200023060-00003","volume":"23","author":"TC Trujillo","year":"2000","unstructured":"Trujillo TC, Nolan PE. Antiarrhythmic agents. Drug Saf. 2000;23(6):509\u201332.","journal-title":"Drug Saf"},{"issue":"11","key":"661_CR10","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1161\/01.CIR.101.11.1297","volume":"101","author":"SJ Connolly","year":"2000","unstructured":"Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS) a randomized trial of the implantable cardioverter defibrillator against Amiodarone. Circulation. 2000;101(11):1297\u2013302.","journal-title":"Circulation"},{"issue":"14","key":"661_CR11","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMsa051989","volume":"353","author":"GD Sanders","year":"2005","unstructured":"Sanders GD, Hlatky MA, Owens DK. Cost-Effectiveness of implantable Cardioverter\u2013Defibrillators. N Engl J Med. 2005;353(14):1471\u201380.","journal-title":"N Engl J Med"},{"issue":"6","key":"661_CR12","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2011.02.1180","volume":"14","author":"A Gandjour","year":"2011","unstructured":"Gandjour A, Dipl-Ges-\u00d6k AH, Adarkwah CC. Cost-Effectiveness of implantable defibrillators after myocardial infarction based on 8-Year Follow-Up data (MADIT II). Value Health. 2011;14(6):812\u20137.","journal-title":"Value Health"},{"key":"661_CR13","doi-asserted-by":"publisher","first-page":"502","DOI":"10.7705\/biomedica.4235","volume":"39","author":"S Atehort\u00faa","year":"2019","unstructured":"Atehort\u00faa S, Senior JM, Castro P, Ceballos M, Saldarriaga C, Giraldo N, et al. Cost-utility analysis of an implantable cardioverterdefibrillator for the treatment of patients with ischemic or non-ischemic new York heart association class II or III heart failure in Colombia. Biom\u00e9dica. 2019;39:502\u201312.","journal-title":"Biom\u00e9dica"},{"key":"661_CR14","unstructured":"Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied methods of Cost-effectiveness analysis in healthcare. OUP Oxford; 2011."},{"key":"661_CR15","doi-asserted-by":"crossref","unstructured":"Edlin R, McCabe C, Hulme C, Hall P, Wright J. Cost effectiveness modelling for health technology assessment: A practical course. Springer International Publishing; 2015.","DOI":"10.1007\/978-3-319-15744-3"},{"key":"661_CR16","unstructured":"Central bank of the Islamic Republic of Iran. Foreign Exchange Rates [Available from: https:\/\/www.cbi.ir\/exrates\/rates_en.aspx]"},{"key":"661_CR17","unstructured":"World Bank. GDP per capita. 2019 [Available from: https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD]"},{"issue":"3","key":"661_CR18","first-page":"181","volume":"14","author":"A Mahboub-Ahari","year":"2014","unstructured":"Mahboub-Ahari A, Pourreza A, Sari AA, Rahimi Foroushani A, Heydari H. Stated time preferences for health: a systematic review and meta analysis of private and social discount rates. J Res Health Sci. 2014;14(3):181\u20136.","journal-title":"J Res Health Sci"},{"issue":"1","key":"661_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.hrtlng.2015.10.001","volume":"45","author":"NK Humphreys","year":"2016","unstructured":"Humphreys NK, Lowe R, Rance J, Bennett PD. Living with an implantable cardioverter defibrillator: the patients\u2019 experience. Heart Lung: J Crit Care. 2016;45(1):34\u201340.","journal-title":"Heart Lung: J Crit Care"},{"issue":"5","key":"661_CR20","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/heart.87.5.488","volume":"87","author":"SF Sears","year":"2002","unstructured":"Sears SF, Conti JB. Quality of life and psychological functioning of Icd patients. Heart. 2002;87(5):488\u201393.","journal-title":"Heart"},{"issue":"5","key":"661_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1161\/hc0502.103330","volume":"105","author":"EB Schron","year":"2002","unstructured":"Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 2002;105(5):589\u201394.","journal-title":"Circulation"},{"issue":"1","key":"661_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ahj.2010.04.021","volume":"160","author":"GD Sanders","year":"2010","unstructured":"Sanders GD, Kong MH, Al-Khatib SM, Peterson ED. Cost-effectiveness of implantable cardioverter defibrillators in patients\u2009\u2265\u200965 years of age. Am Heart J. 2010;160(1):122\u201331.","journal-title":"Am Heart J"},{"issue":"2","key":"661_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1524-4733.2009.00608.x","volume":"13","author":"RA Ribeiro","year":"2010","unstructured":"Ribeiro RA, Stella SF, Camey SA, Zimerman LI, Pimentel M, Rohde LE, et al. Cost-effectiveness of implantable cardioverter-defibrillators in brazil: primary prevention analysis in the public sector. Value Health: J Int Soc Pharmacoeconomics Outcomes Res. 2010;13(2):160\u20138.","journal-title":"Value Health: J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"661_CR24","doi-asserted-by":"crossref","unstructured":"Cowie MR, Marshall D, Drummond M, Ferko N, Maschio M, Ekman M et al. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2009;11(6):716-26.","DOI":"10.1093\/europace\/eup068"},{"issue":"1","key":"661_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1540-8167.2012.02413.x","volume":"24","author":"K Noyes","year":"2013","unstructured":"Noyes K, Veazie P, Hall WJ, Zhao H, Buttaccio A, Thevenet-Morrison K, et al. Cost\u2010Effectiveness of cardiac resynchronization therapy in the MADIT\u2010CRT trial. J Cardiovasc Electrophys. 2013;24(1):66\u201374.","journal-title":"J Cardiovasc Electrophys"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00661-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00661-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00661-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:46:44Z","timestamp":1781614004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-025-00661-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["661"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00661-5","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"28 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was conducted in accordance with the principles of the revised Declaration of Helsinki. After explaining the purpose of the study, written informed consent was obtained from all participants. In order to remain anonymous. The participants were reassured about the principles of confidentiality and anonymity, voluntary participation in the study, and the freedom to withdraw from the study at any time without any consequences. The time and place of the interviews were chosen in coordination with the participants. This study was approved by the Ethics Committee of Kerman University of Medical Sciences IR.KMU.REC.1399.537. As this was a non-interventional study, the ethics committee of Kerman University of Medical Sciences allowed the authors to conduct this research and the document about granting permission was sent to the journal editor. also, to obtain the informed consent of illiterate individuals, Informed consent was obtained from their legal guardians and trusted individuals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}